After a median follow-up of 17.8 months, the PFS was not reached in the abemaciclib arm and was reached at 14.7 months in the placebo arm (HR, 0.54; 95% CI, 0.41–0.72;P= .000021).In the final analysis of OS, there was a nonsignificant difference in median survival (median OS, 66.8 months [abemaciclib arm] vs.
53.7 months [placebo arm]; HR, 0.804; 95% CI, 0.637–1.015;P= .066).[20][Level of evidence B1]The side effect profile of abemaciclib differs from the other CDK4/6 inhibitors.
Diarrhea was the most frequent adverse event in the abemaciclib arm, although most of the diarrhea cases were grade 1.Neutropenia was more common in the abemaciclib arm; however, only 21.1% of participants experienced grade 3 to 4 neutropenia.